Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,341 - 1,360 results of 48,685 for search '(( 50 ((ng decrease) OR (a decrease)) ) OR ( 5 ((mg decrease) OR (mean decrease)) ))', query time: 1.10s Refine Results
  1. 1341
    Probability of medical discharge at 60 days in the different treatment groups.

    Probability of medical discharge at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 1342
    Clinical outcome at 60 days based on SaFi, anakinra and a simplified SCOPE.

    Clinical outcome at 60 days based on SaFi, anakinra and a simplified SCOPE. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 1343
    Comorbidities and severity scales at admission for the different treatment groups.

    Comorbidities and severity scales at admission for the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 1344
    Probability of remaining as an inpatient at 30 days in the different treatment groups.

    Probability of remaining as an inpatient at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 1345
    Probability of medical discharge at 30 days in the different treatment groups.

    Probability of medical discharge at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 1346
    Probability of remaining as an inpatient at 60 days in the different treatment groups.

    Probability of remaining as an inpatient at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 1347
    A simplified SCOPE score.

    A simplified SCOPE score. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 1348
    SH-SY5Y cells are responsive to acute insulin stimulation and altered insulin signaling impacts choline uptake by CHT.

    SH-SY5Y cells are responsive to acute insulin stimulation and altered insulin signaling impacts choline uptake by CHT. by Katherine J. Fishwick (768451)

    Published 2015
    Save to List
    Saved in:
  9. 1349
    Post-losartan treatment prevented SARS-CoV-2 spike protein-induced decreased cognitive impairment but not pre-losartan treatment.

    Post-losartan treatment prevented SARS-CoV-2 spike protein-induced decreased cognitive impairment but not pre-losartan treatment. by Mackenzi Meier (19251139)

    Published 2024
    Save to List
    Saved in:
  10. 1350
    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst.

    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  11. 1351
    Exposure of HOB to chemotherapeutic agents or rTGF-β1 decreased the expression of CXCL-12 and diminished support of pro-B cell chemotaxis.

    Exposure of HOB to chemotherapeutic agents or rTGF-β1 decreased the expression of CXCL-12 and diminished support of pro-B cell chemotaxis. by Stephanie L. Rellick (182765)

    Published 2012
    Save to List
    Saved in:
  12. 1352
    AA-deficient <i>sfx</i> mice had decreased articular cartilage.

    AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

    Published 2019
    Save to List
    Saved in:
  13. 1353
    Assays of TUNEL revealed a decreased number of apoptotic cell after oroxylin A treatment.

    Assays of TUNEL revealed a decreased number of apoptotic cell after oroxylin A treatment. by Shu-Fang Lin (4167091)

    Published 2017
    Save to List
    Saved in:
  14. 1354
    Type and duration of leisure-time activities performed 5 years after RYGB.

    Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

    Published 2022
    Save to List
    Saved in:
  15. 1355
    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months.

    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

    Published 2021
    Save to List
    Saved in:
  16. 1356
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1357
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1358
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1359
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1360
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: